204 related articles for article (PubMed ID: 32107846)
1. Bispecific human IL2-CCR4 immunotoxin targets human cutaneous T-cell lymphoma.
Wang H; Wang Z; Zhang H; Qi Z; Johnson AC; Mathes D; Pomfret EA; Rubin E; Huang CA; Wang Z
Mol Oncol; 2020 May; 14(5):991-1000. PubMed ID: 32107846
[TBL] [Abstract][Full Text] [Related]
2. CCR4-IL2 bispecific immunotoxin is more effective than brentuximab for targeted therapy of cutaneous T-cell lymphoma in a mouse CTCL model.
Wang Z; Ma J; Zhang H; Ramakrishna R; Mintzlaff D; Mathes DW; Pomfret EA; Lucia MS; Gao D; Haverkos BM; Wang Z
FEBS Open Bio; 2023 Jul; 13(7):1309-1319. PubMed ID: 37157185
[TBL] [Abstract][Full Text] [Related]
3. Ontak-like human IL-2 fusion toxin.
Wang Z; Zheng Q; Zhang H; Bronson RT; Madsen JC; Sachs DH; Huang CA; Wang Z
J Immunol Methods; 2017 Sep; 448():51-58. PubMed ID: 28551309
[TBL] [Abstract][Full Text] [Related]
4. Diphtheria-toxin based anti-human CCR4 immunotoxin for targeting human CCR4(+) cells in vivo.
Wang Z; Wei M; Zhang H; Chen H; Germana S; Huang CA; Madsen JC; Sachs DH; Wang Z
Mol Oncol; 2015 Aug; 9(7):1458-70. PubMed ID: 25958791
[TBL] [Abstract][Full Text] [Related]
5. Toxicology, pharmacokinetics, and immunogenicity studies of CCR4-IL2 bispecific immunotoxin in rats and minipigs.
Wang Z; Ramakrishna R; Wang Y; Qiu Y; Ma J; Mintzlaff D; Zhang H; Li B; Hammell B; Lucia MS; Pomfret E; Su AA; Washington KM; Mathes DW; Wang Z
Eur J Pharmacol; 2024 Apr; 968():176408. PubMed ID: 38367684
[TBL] [Abstract][Full Text] [Related]
6. Modified DT-IL2 fusion toxin targeting uniquely IL2Ralpha expressing leukemia cell lines - Construction and characterization.
Potala S; Verma RS
J Biotechnol; 2010 Jul; 148(2-3):147-55. PubMed ID: 20580754
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-2 fusion toxin: targeted therapy for cutaneous T cell lymphoma.
Foss FM
Ann N Y Acad Sci; 2001 Sep; 941():166-76. PubMed ID: 11594570
[TBL] [Abstract][Full Text] [Related]
8. Dosing optimization of CCR4 immunotoxin for improved depletion of CCR4
Wang Z; Louras NJ; Lellouch AG; Pratts SG; Zhang H; Wang H; Huang CA; Cetrulo CL; Madsen JC; Sachs DH; Wang Z
Mol Oncol; 2018 Aug; 12(8):1374-1382. PubMed ID: 29873181
[TBL] [Abstract][Full Text] [Related]
9. Development of a diphtheria toxin-based recombinant porcine IL-2 fusion toxin for depleting porcine CD25+ cells.
Peraino JS; Schenk M; Li G; Zhang H; Farkash EA; Sachs DH; Huang CA; Duran-Struuck R; Wang Z
J Immunol Methods; 2013 Dec; 398-399():33-43. PubMed ID: 24055128
[TBL] [Abstract][Full Text] [Related]
10. Treg depletion in non-human primates using a novel diphtheria toxin-based anti-human CCR4 immunotoxin.
Wang Z; Pratts SG; Zhang H; Spencer PJ; Yu R; Tonsho M; Shah JA; Tanabe T; Powell HR; Huang CA; Madsen JC; Sachs DH; Wang Z
Mol Oncol; 2016 Apr; 10(4):553-65. PubMed ID: 26643572
[TBL] [Abstract][Full Text] [Related]
11. Bexarotene and DAB(389)IL-2 (denileukin diftitox, ONTAK) in treatment of cutaneous T-cell lymphomas: algorithms.
Duvic M
Clin Lymphoma; 2000 Nov; 1 Suppl 1():S51-5. PubMed ID: 11707865
[TBL] [Abstract][Full Text] [Related]
12. Diphtheria toxin-based bivalent human IL-2 fusion toxin with improved efficacy for targeting human CD25(+) cells.
Peraino JS; Zhang H; Rajasekera PV; Wei M; Madsen JC; Sachs DH; Huang CA; Wang Z
J Immunol Methods; 2014 Mar; 405():57-66. PubMed ID: 24462799
[TBL] [Abstract][Full Text] [Related]
13. Targeted therapies: Denileukin diftitox--a step towards a 'magic bullet' for CTCL.
Kadin ME; Vonderheid EC
Nat Rev Clin Oncol; 2010 Aug; 7(8):430-2. PubMed ID: 20668480
[No Abstract] [Full Text] [Related]
14. A comparison of an anti-CD25 immunotoxin, Ontak and anti-CD25 microbeads for their ability to deplete alloreactive T cells in vitro.
Vaclavkova P; Cao Y; Wu LK; Michalek J; Vitetta ES
Bone Marrow Transplant; 2006 Mar; 37(6):559-67. PubMed ID: 16444279
[TBL] [Abstract][Full Text] [Related]
15. Denileukin diftitox.
Figgitt DP; Lamb HM; Goa KL
Am J Clin Dermatol; 2000; 1(1):67-72; discussion 73. PubMed ID: 11702307
[TBL] [Abstract][Full Text] [Related]
16. Biologic correlates of response and survival in patients with cutaneous T-cell lymphoma treated with denileukin diftitox.
Chin KM; Foss FM
Clin Lymphoma Myeloma; 2006 Nov; 7(3):199-204. PubMed ID: 17229335
[TBL] [Abstract][Full Text] [Related]
17. Targeted therapy to the IL-2R using diphtheria toxin and caspase-3 fusion proteins modulates Treg and ameliorates inflammatory colitis.
Yarkoni S; Sagiv Y; Kaminitz A; Farkas DL; Askenasy N
Eur J Immunol; 2009 Oct; 39(10):2850-64. PubMed ID: 19735074
[TBL] [Abstract][Full Text] [Related]
18. Two novel therapies for the treatment of cutaneous T-cell lymphoma.
LeMaistre CF
Clin Lymphoma; 2000 Nov; 1 Suppl 1():S7. PubMed ID: 11707856
[No Abstract] [Full Text] [Related]
19. Biological correlates of acute hypersensitivity events with DAB(389)IL-2 (denileukin diftitox, ONTAK) in cutaneous T-cell lymphoma: decreased frequency and severity with steroid premedication.
Foss FM; Bacha P; Osann KE; Demierre MF; Bell T; Kuzel T
Clin Lymphoma; 2001 Mar; 1(4):298-302. PubMed ID: 11707845
[TBL] [Abstract][Full Text] [Related]
20. CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma.
Talpur R; Jones DM; Alencar AJ; Apisarnthanarax N; Herne KL; Yang Y; Duvic M
J Invest Dermatol; 2006 Mar; 126(3):575-83. PubMed ID: 16410787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
